{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:04:59Z","timestamp":1773234299698,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,4,16]],"date-time":"2004-04-16T00:00:00Z","timestamp":1082073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1038\/sj.eye.6701405","type":"journal-article","created":{"date-parts":[[2004,4,19]],"date-time":"2004-04-19T12:10:07Z","timestamp":1082376607000},"page":"41-44","source":"Crossref","is-referenced-by-count":31,"title":["The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication"],"prefix":"10.1038","volume":"19","author":[{"given":"J L","family":"Best","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J F","family":"Acheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,4,16]]},"reference":[{"key":"BF6701405_CR1","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1111\/j.1528-1157.1995.tb06003.x","volume":"36","author":"E Ben-Menachem","year":"1995","unstructured":"Ben-Menachem E . Vigabatrin. Epilepsia 1995; 36: S95\u2013S104.","journal-title":"Epilepsia"},{"key":"BF6701405_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","volume":"38","author":"AG Marson","year":"1997","unstructured":"Marson AG, Kadir ZA, Hutton JL, Chadwick DW . The new antiepileptic drugs: a systemic review of their efficacy and tolerability. Epilepsia 1997; 38: 859\u2013880.","journal-title":"Epilepsia"},{"key":"BF6701405_CR3","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/WNL.57.10.1916","volume":"57","author":"Nousianen","year":"2001","unstructured":"Nousianen, Mantyjarvi M, Kalviainen R . No reversion in vigabatrin-associated field defects. Neurology 2001; 57: 1916\u20131917.","journal-title":"Neurology"},{"key":"BF6701405_CR4","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1111\/j.1528-1157.1999.tb01599.x","volume":"40","author":"JM Wild","year":"1999","unstructured":"Wild JM, Martinez C, Reinshagen G, Harding G . Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40(12): 1784\u20131794.","journal-title":"Epilepsia"},{"key":"BF6701405_CR5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1212\/WNL.53.5.922","volume":"53","author":"R Kalviainen","year":"1999","unstructured":"Kalviainen R, Nousiainen I, Mantyjarvi M, Nikoskelainer E, Pastaner J, Pastaner K, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922\u2013926.","journal-title":"Neurology"},{"key":"BF6701405_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/jnnp.67.6.716","volume":"67","author":"MC Lawden","year":"1999","unstructured":"Lawden MC, Eke T, Degg C, Harding GFA, Wild JM . Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67: 716\u2013722.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BF6701405_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/sj.eye.6700168","volume":"16","author":"WD Newman","year":"2002","unstructured":"Newman WD, Tocher K, Acheson J . Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 2002; 16: 567\u2013571.","journal-title":"Eye"},{"key":"BF6701405_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1212\/WNL.55.1.40","volume":"55","author":"MA Johnson","year":"2000","unstructured":"Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR . Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000; 55: 40\u201345.","journal-title":"Neurology"},{"key":"BF6701405_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/seiz.2000.0397","volume":"9","author":"K Krakow","year":"2000","unstructured":"Krakow K, Polizzi G, Riordan- Eva P, Holder G, MacLeod WN, Fish DR . Recovery of visual field constriction following discontinuation of vigabatrin. Seizure 2000; 9: 287\u2013290.","journal-title":"Seizure"},{"key":"BF6701405_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s100720070096","volume":"21","author":"L Giordano","year":"2000","unstructured":"Giordano L, Valseriati D, Vignoli A, Morescalchi F, Gandolfo E . Another case of reversibility of visual field defects induced by vigabatrin monotherapy: is young age a favourable factor? Neurol Sci 2000; 21: 185\u2013186.","journal-title":"Neurol Sci"},{"issue":"Suppl","key":"BF6701405_CR11","first-page":"144","volume":"41","author":"G Kraemer","year":"2000","unstructured":"Kraemer G, Ried S, Landau K, Harding GFA . Vigabatrin. Reversibility of severe concentric visual field defects after early detection and drug withdrawal:a case report. Epilepsia 2000; 41(Suppl): 144.","journal-title":"Epilepsia"},{"key":"BF6701405_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1023\/A:1014615517996","volume":"104","author":"Kors Van Der Torren","year":"2002","unstructured":"Van Der Torren Kors, Graniewski-Wijnands HS, Polak BCP . Visual field and electrophysiological abnormalities due to vigabatrin. Documenta. Ophthalmologica 2002; 104: 181\u2013188.","journal-title":"Ophthalmologica"},{"key":"BF6701405_CR13","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S0161-6420(01)00638-8","volume":"108","author":"SG Coupland","year":"2001","unstructured":"Coupland SG, Zackro DH, Leonard BC, Ross TM . Vigabatrin effect on inner retinal function. Ophthalmology 2001; 108: 1493\u20131496.","journal-title":"Ophthalmology"},{"key":"BF6701405_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","volume":"314","author":"T Eke","year":"1997","unstructured":"Eke T, Talbot JF, Lawden MC . Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314: 180\u2013181.","journal-title":"BMJ"},{"key":"BF6701405_CR15","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/bmj.314.7095.1693a","volume":"314","author":"EA Wilson","year":"1997","unstructured":"Wilson EA, Brodie MJ, Wong IC, Mawer GE, Sander JWAS, Blackwell N et al. Severe persistent visual field constriction associated with vigabatrin (multiple letters). BMJ 1997; 314: 1693\u20131695.","journal-title":"BMJ"},{"key":"BF6701405_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1136\/bmj.316.7126.232","volume":"316","author":"HFA Harding","year":"1998","unstructured":"Harding HFA, Mackenzie R, Klistorner A . Severe persistent visual field constriction associated with vigabatrin. BMJ 1998; 316: 232\u2013233.","journal-title":"BMJ"},{"key":"BF6701405_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1046\/j.1528-1157.2001.49299.x","volume":"42","author":"SR Paul","year":"2001","unstructured":"Paul SR, Krauss GL, Miller NR, Medura M, Miller TA, Johnson MA et al. Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. Epilepsia 2001; 42: 525\u2013530.","journal-title":"Epilepsia"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6701405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6701405","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6701405.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:16:29Z","timestamp":1684412189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6701405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,16]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["BF6701405"],"URL":"https:\/\/doi.org\/10.1038\/sj.eye.6701405","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,16]]}}}